Royal Bank of Canada
CCCC icon

Royal Bank of Canada’s C4 Therapeutics CCCC Stock Holding History

Royal Bank of Canada’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Buy
680
+9
+1% +$21 ﹤0.01% 6835
2025
Q4 		$1K Sell
671
-181,969
-100% -$431K ﹤0.01% 6969
2025
Q3 		$405K Sell
182,640
-56,317
-24% -$135K ﹤0.01% 4639
2025
Q2 		$342K Buy
238,957
+233,392
+4,194% +$339K ﹤0.01% 4752
2025
Q1 		$9K Sell
5,565
-2,555
-31% -$7.62K ﹤0.01% 6184
2024
Q4 		$29K Buy
8,120
+1,815
+29% +$9.03K ﹤0.01% 5940
2024
Q3 		$36K Sell
6,305
-753
-11% -$4.53K ﹤0.01% 5845
2024
Q2 		$33K Sell
7,058
-16,792
-70% -$100K ﹤0.01% 5840
2024
Q1 		$194K Buy
23,850
+23,307
+4,292% +$181K ﹤0.01% 4714
2023
Q4 		$3K Sell
543
-5,261
-91% -$12K ﹤0.01% 6713
2023
Q3 		$11K Buy
5,804
+5,244
+936% +$16K ﹤0.01% 6378
2023
Q2 		$1K Sell
560
-2,373
-81% -$7.63K ﹤0.01% 6970
2023
Q1 		$9K Sell
2,933
-5,353
-65% -$31.5K ﹤0.01% 6357
2022
Q4 		$49K Buy
8,286
+7,229
+684% +$59.9K ﹤0.01% 5886
2022
Q3 		$9K Buy
1,057
+277
+36% +$2.88K ﹤0.01% 6467
2022
Q2 		$6K Sell
780
-1,676
-68% -$14.7K ﹤0.01% 6563
2022
Q1 		$60K Sell
2,456
-9,019
-79% -$219K ﹤0.01% 5972
2021
Q4 		$369K Buy
11,475
+3,850
+50% +$152K ﹤0.01% 4746
2021
Q3 		$341K Buy
7,625
+2,448
+47% +$105K ﹤0.01% 4669
2021
Q2 		$196K Buy
5,177
+4,272
+472% +$153K ﹤0.01% 5091
2021
Q1 		$33K Sell
905
-118
-12% -$4.69K ﹤0.01% 6136
2020
Q4 		$34K Buy
+1,023
New +$29.7K ﹤0.01% 5815

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada's CCCC Position: Q1 2026 in Review

Royal Bank of Canada increased its C4 Therapeutics (CCCC) stake by 1.3% in Q1 2026, buying an estimated $21 and bringing the position to 680 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6835.

Royal Bank of Canada first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $405K in Q3 2025. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Royal Bank of Canada held 680 shares of C4 Therapeutics worth $1K as of Q1 2026.
  • Royal Bank of Canada bought 9 C4 Therapeutics shares in Q1 2026, an estimated $21.
  • C4 Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6835 holding.
  • Royal Bank of Canada first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's C4 Therapeutics position peaked at $405K in Q3 2025.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.